Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer

Cancer Gene Therapy volume 25, pages 10–17 (2018)Cite this article

Subjects

Abstract

More and more evidences have ensured the crucial functions of long non-coding RNAs (lncRNAs) in multiple tumors. It has been discovered that lncRNA-SNHG16 is involved in many tumors. Even so, it is still necessary to study SNHG16 comprehensively in bladder cancer. In terms of our study, the level of SNHG16 both in the tumor tissues and cell lines was measured and the relationship among SNHG16, clinicopathological traits and prognosis was explored. Interference assays were applied to determine the biological functions of SNHG16. It was discovered that the level of SNHG16 was evidently enhanced both in tissues and cell lines of bladder cancer. Patients with highly expressed SNHG16 suffered from poor overall survival. Multivariable Cox proportional hazards regression analysis implied that highly expressed SNHG16 could be used as an independent prognostic marker. It could be known from functional assays that silenced SNHG16 impaired cell proliferation, owing to the effects of SNHG16 on cell cycle and apoptosis. Finally, mechanism experiments revealed that SNHG16 could epigenetically silence the expression of p21. The facts above pointed out that lncRNA-SNHG16 might be quite vital for the diagnosis and development of bladder cancer, and could even become an important therapeutic target for bladder cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: SNHG16 is significantly expressed in bladder cancer tissues and cells
Fig. 2
Fig. 3: Knockdown of lncRNA-SNHG16 influences proliferation of BC cells
Fig. 4: Knockdown of lncRNA-SNHG16 causes cell cycle arrest at G1 phase and promotes cell apoptosis
Fig. 5: SNHG16 exerts its function in a p21-dependent manner
Fig. 6: The silence of p21 potentially involves in the oncogenic function of SNHG16

Similar content being viewed by others

References

  1. Bansal N, Gupta AK, Gupta A, Sankhwar SN, Mahdi AA. Serum-based protein biomarkers of bladder cancer: A pre- and post-operative evaluation. J Pharm Biomed Anal. 2016;124:22–5.

    Article  PubMed  CAS  Google Scholar 

  2. Racioppi M, D’Agostino D, Totaro A, Pinto F, Sacco E, D’Addessi A, et al. Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urol Int. 2012;88:249–58.

    Article  PubMed  CAS  Google Scholar 

  3. Sofra M, Fei PC, Fabrizi L, Marcelli ME, Claroni C, Gallucci M, et al. Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results. J Exp Clin Cancer Res. 2013;32:6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Rose TL, Milowsky MI. Improving systemic chemotherapy for bladder cancer. Curr Oncol Rep. 2016;18:27.

    Article  PubMed  CAS  Google Scholar 

  5. Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting non-coding RNAs in disease. J Clin Invest. 2017;127:761–71.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chandra Gupta S, Nandan Tripathi Y. Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer. 2016;140:1955–67.

  7. Deng H, Zhang J, Shi J, Guo Z, He C, Ding L, et al. Role of long non-coding RNA in tumor drug resistance. Tumour Biol. 2016;37:11623–31.

    Article  PubMed  CAS  Google Scholar 

  8. Ning L, Li Z, Wei D, Chen H, Yang C. LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma. Cancer Biomark. 2017;19:75–83.

  9. Wu ZJ, Li Y, Wu YZ, Wang Y, Nian WQ, Wang LL, et al. Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-beta signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21:706–14.

    PubMed  Google Scholar 

  10. Xiao JN, Yan TH, Yu RM, Gao Y, Zeng WL, Lu SW, et al. Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression. J Cancer Res Clin Oncol. 2017;143:981–90.

  11. Zhang S, Wang Y, Chen M, Sun L, Han J, Elena VK, et al. CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma. Sci Rep. 2017;7:44033.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chen X, Gao G. Long noncoding RNA PVT1 as a novel diagnostic biomarker and therapeutic target for melanoma. Biomed Res Int. 2017;2017:7038579.

  13. Cai C, Huo Q, Wang X, Chen B, Yang Q. SNHG16 contributes to breast cancer cell migration by competitively binding miR-98 with E2F5. Biochem Biophys Res Commun. 2017;485:272–8.

    Article  PubMed  CAS  Google Scholar 

  14. Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, et al. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol. 2016;10:1266–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Duan W, Du L, Jiang X, Wang R, Yan S, Xie Y, et al. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer. Oncotarget. 2016;7:78850–8.

    PubMed  PubMed Central  Google Scholar 

  16. Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, et al. LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res. 2016;76:6299–310.

    Article  PubMed  CAS  Google Scholar 

  17. Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ. Long intergenic noncoding RNA 00511 Acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Acids. 2016;5:e385.

    Article  CAS  Google Scholar 

  18. Hon CC, Ramilowski JA, Harshbarger J, Bertin N, Rackham OJ, Gough J, et al. An atlas of human long non-coding RNAs with accurate 5’ ends. Nature. 2017;543:199–204.

    Article  PubMed  CAS  Google Scholar 

  19. Li W, Li H, Zhang L, Hu M, Li F, Deng J, et al. LINC00672 contributes p53-mediated gene suppression and promotes endometrial cancer chemosensitivity. J Biol Chem 2017;292:5801-13.

  20. Liu JN, Shangguan YM. Long non-coding RNA CARLo-5 upregulation associates with poor prognosis in patients suffering gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21:530–4.

    Article  PubMed  CAS  Google Scholar 

  21. Wang TH, Chan CW, Fang JY, Shih YM, Liu YW, Wang TV, et al. 2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells. Cell Death Dis. 2017;8:e2638.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Zhang H, Xiong Y, Xia R, Wei C, Shi X, Nie F. The pseudogene-derived long noncoding RNA SFTA1P is down-regulated and suppresses cell migration and invasion in lung adenocarcinoma. Tumour Biol. 2017;39:1010428317691418.

    PubMed  Google Scholar 

  23. Li T, Meng XL, Yang WQ. Long noncoding RNA PVT1 acts as a “sponge” to inhibit microRNA-152 in gastric cancer cells. Digest Dis Sci. 2017;62:3021–28.

  24. Li Y, Wu Z, Yuan J, Sun L, Lin L, Huang N, et al. Long non-coding RNA MALAT1 promotes gastric cancer tumorigenicity and metastasis by regulating vasculogenic mimicry and angiogenesis. Cancer Lett 2017;395:31–44.

  25. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We thank the laboratory members.

Author information

Author notes

    Authors and Affiliations

    1. Urology Department, Affiliated hospital of jining medical college, Shandong, 272000, China

      Xianxiang Cao, Jing Xu & Dong Yue

    Authors
    1. Xianxiang Cao
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jing Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Dong Yue
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Dong Yue.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest

    Additional information

    Xianxiang Cao and Jing Xu authors are contributed equally to this manuscript.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Cao, X., Xu, J. & Yue, D. LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer. Cancer Gene Ther 25, 10–17 (2018). https://doi.org/10.1038/s41417-017-0006-x

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1038/s41417-017-0006-x

    This article is cited by

    Search

    Advanced search

    Quick links